Novartis wins European approval for biosimilar version of Roche’s MabThera

ZURICH (Reuters) - Swiss drugmaker Novartis on Monday said it had won European approval for its biosimilar version of Roche's blockbuster Rituxan as the crosstown rivals go head-to-head on a drug to t…
Read the full story: Reuters: Health News